New Immunotherapy Therapy Approved for Lymphoma Patients

The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy. The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is … Continued

Lymphoma Patient Gets Back on the Court Post-Treatment

For much of his 17 years, Spencer Riley has lived to play basketball. This winter, his favorite sport helped the teenager get back to life. Riley was diagnosed with non-Hodgkin lymphoma in 2016 and treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center that summer. He underwent an intensive three-month treatment cycle: one week of … Continued

Non-Hodgkin Lymphoma and Hodgkin Lymphoma: What’s the Difference?

Although the diseases may sound similar, there is a lot of difference between Hodgkin and non-Hodgkin lymphoma. Both diseases are malignancies of a family of white blood cells known as lymphocytes, which help the body fight off infections and other diseases. Hodgkin lymphoma is marked by the presence of Reed-Sternberg cells, which are mature B … Continued

What are the Different Types of Non-Hodgkin Lymphoma?

Although lymphoma diagnoses are often categorized as either Hodgkin lymphoma or non-Hodgkin lymphoma, there are many subtypes of each disease, with more than 50 subtypes of non-Hodgkin lymphoma alone. Most forms of the more than 70,000 new cases of non-Hodgkin lymphoma diagnosed in the U.S. each year can be broken up into two main subtypes: … Continued